 |
|
Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines
Nicole L. Glazer, MPH;
Sascha Dublin, MD, PhD;
Nicholas L. Smith, PhD, MPH;
Benjamin French, MS;
Lisa A. Jackson, MD, MPH;
Jennifer B. Hrachovec, PharmD;
David S. Siscovick, MD, MPH;
Bruce M. Psaty, MD, PhD;
Susan R. Heckbert, MD, PhD
Arch Intern Med. 2007;167(3):246-252.
Background Guidelines recommend the use of antithrombotic therapy for stroke prevention in patients with atrial fibrillation (AF), but compliance with such guidelines has not been widely studied among patients with newly detected AF. Our objective was to assess compliance with antithrombotic guidelines and to identify patient characteristics associated with warfarin use.
Methods A population-based study of newly detected AF (patient age, 30-84 years) was conducted within a large health plan. Cardiovascular disease risk factors, comorbid conditions, medication use, and international normalized ratios were abstracted from the medical record. Patients were stratified by embolic risk according to American College of Chest Physicians (ACCP) criteria. We analyzed the proportion of patients with AF receiving warfarin or aspirin ( 325 mg/d) during the 6 months following AF. Relative risk regression estimated the association of risk factors and patient characteristics with warfarin use.
Results Overall, 73% of patients (418/572) with newly detected AF had evidence of antithrombotic use after AF onset. Among the 76% (437/572) of patients with AF at high risk for stroke, 59% (257/437) used warfarin, 28% (123/437) used aspirin, and 24% (104/437) used neither. The major predictor of warfarin use was AF classification; intermittent or sustained AF had relative risks for warfarin use of 2.8 (95% confidence interval, 2.2-3.6) and 2.9 (95% confidence interval, 2.2-3.7), respectively, compared with transitory AF.
Conclusions Three quarters of the patients with newly detected AF received antithrombotic therapy, yet many at high risk of stroke did not receive warfarin. Atrial fibrillation classification, rather than stroke risk factors, was strongly associated with warfarin use.
Author Affiliations: Cardiovascular Health Research Unit and Department of Epidemiology (Ms Glazer and Drs Smith, Siscovick, Psaty, and Heckbert), and Departments of Biostatistics (Mr French), Medicine (Drs Siscovick and Psaty), and Health Services (Dr Psaty), University of Washington, VA Puget Sound Health Care System (Dr Dublin), and Center for Health Studies, Group Health Cooperative (Drs Jackson, Hrachovec, and Heckbert), Seattle.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
The Influence of Patient Adherence on Anticoagulation Control With Warfarin: Results From the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study
Stephen E. Kimmel, Zhen Chen, Maureen Price, Catherine S. Parker, Joshua P. Metlay, Jason D. Christie, Colleen M. Brensinger, Craig W. Newcomb, Frederick F. Samaha, and Robert Gross
Arch Intern Med. 2007;167(3):229-235.
ABSTRACT
| FULL TEXT
Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control: Results From SPORTIF III and V
Harvey D. White, Michael Gruber, Jan Feyzi, Scott Kaatz, Hung-Fat Tse, Steen Husted, and Gregory W. Albers
Arch Intern Med. 2007;167(3):239-245.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Incident Stroke and Mortality Associated With New-Onset Atrial Fibrillation in Patients Hospitalized With Severe Sepsis
Walkey et al.
JAMA 2011;306:2248-2254.
ABSTRACT
| FULL TEXT
A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks
Bajorek
Therapeutic Advances in Drug Safety 2011;2:45-58.
ABSTRACT
Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation
Medi et al.
Stroke 2010;41:2705-2713.
ABSTRACT
| FULL TEXT
Dabigatran Challenges Warfarin's Superiority for Stroke Prevention in Atrial Fibrillation
Schwartz and Albers
Stroke 2010;41:1307-1309.
FULL TEXT
Optimal Anticoagulation Therapy in Patients With Valvular Heart Disease or Atrial Fibrillation
McLeod and Gersh
Arch Intern Med 2009;169:2032-2033.
FULL TEXT
The case-crossover study design in pharmacoepidemiology
'Chris' Delaney and Suissa
Stat Methods Med Res 2009;18:53-65.
ABSTRACT
Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
WRITING GROUP MEMBERS et al.
Circulation 2009;119:e21-e181.
FULL TEXT
Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert et al.
Arch Intern Med 2008;168:826-831.
ABSTRACT
| FULL TEXT
New oral anticoagulants in atrial fibrillation
Turpie
Eur Heart J 2008;29:155-165.
ABSTRACT
| FULL TEXT
The Year in Epidemiology, Health Services Research, and Outcomes Research
Krumholz and Masoudi
J Am Coll Cardiol 2007;50:2254-2262.
FULL TEXT
Warfarin Therapy in Clinical Practice
JWatch Neurology 2007;2007:2-2.
FULL TEXT
Antithrombotic Therapy for Atrial Fibrillation
JWatch Oncology and Hematology 2007;2007:1-1.
FULL TEXT
|
